-  ELIGIBILITY:

        INCLUSION CRITERIA GENERAL:

          -  Patients must be at least 18 years of age.

          -  Patients must have adequately controlled blood pressure on a maximum of three
             antihypertensive medications.

          -  Patients who have the following clinical conditions are considered to be at increased
             risk for cardiac toxicities.

        Patients with any cardiac history of the following conditions within 1 year prior to study
        enrollment are excluded from the study:

          -  Prior events including myocardial infarction, pericardial effusion, and myocarditis.

          -  Prior cardiac arrhythmia including atrial fibrillation and atrial flutter, or
             requiring concurrent use of drugs or biologics with pro-arrhythmic potential.

          -  NYHA Class II or greater heart failure.

          -  If cardiac function assessment is clinically indicated or performed, an LVEF less than
             normal per institutional guidelines, or <55%, if threshold for normal is not otherwise
             specified by institutional guidelines.

          -  QTc prolongation >470 msec or other significant ECG abnormality noted within 14 days
             of treatment.

          -  Hypertensive crisis or hypertensive encephalopathy.

          -  Clinically significant peripheral vascular disease or vascular disease, including
             rapidly growing aortic aneurysm or abdominal aortic aneurysm >5 cm or aortic
             dissection.

          -  Unstable angina.

               -  Eligibility for patients with asymptomatic and a previous diagnosis of immune or
                  inflammatory colitis, or patients with chronic diarrhea > 1 month without immune
                  or inflammatory colitis is a PI decision on an individual patient basis.

               -  Patients with a history of cerebrovascular accident or transient ischemic attack
                  within 1 year prior to study enrollment are not eligible.

               -  Patients with a history of previous clinical diagnosis of tuberculosis are not
                  eligible.

               -  Patients with a history of auto-immune disease requiring steroid maintenance, or
                  history of primary immunodeficiency are not eligible.

               -  HIV-positive patients on antiretroviral therapy are ineligible because of
                  potential pharmacokinetic interactions with study drugs, however, patients with
                  long-standing (>5 years) HIV on antiretroviral therapy > 1 month (undetectable
                  HIV viral load and CD4 count > 150 cells/microL) may be eligible if the PI
                  determines no anticipated clinically significant drug-drug interactions.

               -  HBV-or HCV-positive patients are ineligible because of potential reactivation of
                  hepatitis virus following steroids.

               -  Patients with a history of allergic reactions attributed to compounds of similar
                  chemical or biologic composition to MEDI4736, olaparib, cediranib, or to other
                  humanized monoclonal antibodies, or a history of anaphylaxis, angioedema,
                  laryngeal edema, serum sickness, or uncontrolled asthma, are not eligible.

               -  Patients who have had prior immune checkpoint inhibitors, such as MEDI4736 or
                  other PD1 or PD-L1 inhibitors or an anti-CTLA4 therapy are eligible.

               -  Pregnant and breastfeeding women are excluded from this study.

               -  Patients with any other concomitant or prior invasive malignancies are
                  ineligible.

        PHASE II MEDI4736 PLUS OLAPARIB OR CEDIRANIB STUDY ELIGIBILITY CRITERIA - OVARIAN CANCER

          -  Patients must have histologically or cytologically confirmed persistent or recurrent
             ovarian, fallopian tube, or primary peritoneal cancer and have received at least two
             prior regimens or who are platinum resistant or refractory during or after a first
             platinum containing regimen.

          -  Patients must have at least one lesion deemed safe to biopsy and be willing to undergo
             a mandatory baseline biopsy.

          -  Patients are allowed to have received prior PARPi, and/or anti-angiogenesis therapy
             including but not limited to thalidomide, bevacizumab, sunitinib, sorafenib, or other
             anti-angiogenics. However, patients who were treated with both olaparib and cediranib,
             either in combination or sequentially are not eligible. For this study, BSI-201
             (iniparib) is not considered as PARPi.

        PHASE II STUDY MEDI4736 PLUS OLAPARIB ELIGIBILITY CRITERIA TRIPLE NEGATIVE BREAST CANCER

          -  Patients must have histologically confirmed persistent or recurrent triple-negative
             breast cancer (TNBC)

          -  ER/PR/HER2 status needs to be documented either by an outside source or at NCI.

          -  Documentation of germline BRCA1 and BRCA2 mutation (gBRCAm) status will be required
             for eligibility.

          -  Patients must have measurable disease as defined by RECIST v1.1.

          -  Patients must have at least one lesion deemed safe to biopsy and be willing to undergo
             a mandatory baseline biopsy.

          -  Patients who have received prior PARPi are ineligible.

          -  Patients must not have evidence of CNS metastasis or leptomeningeal disease within one
             year prior to enrollment.

        PHASE II MEDI4736 PLUS OLAPARIB OR CEDIRANIB STUDY ELIGIBILITY CRITERIA - NON-SMALL CELL
        LUNG CANCER

          -  Histologically or cytologically confirmed advanced NSCLC with at least one prior line
             of platinum-based chemotherapy (or treatment with EGFR, ALK, or BRAF-targeted tyrosine
             kinase inhibitors if tumors harbor an EGFR-sensitizing mutation, ALK translocation, or
             BRAF V600E mutation, respectively).

          -  Patients must have measurable disease as defined by RECIST v1.1.

          -  Patients must have at least one lesion deemed safe to biopsy and be willing to undergo
             a mandatory baseline biopsy.

          -  Patients who have received anti-angiogenesis therapy are eligible, including but not
             limited to thalidomide, bevacizumab, sunitinib, sorafenib, or other anti-angiogenics.
             However, patients who were treated with cediranib, either in combination or
             monotherapy are not eligible.

          -  Current or prior use of immunosuppressive medication within 28 days before the first
             dose of MEDI4736, with the exception of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of
             prednisone or an equivalent corticosteroid.

          -  Patients who have had prior PARPi are not eligible.

          -  Patients with prior history of pneumonitis and/or interstitial lung disease will be
             excluded.

        PHASE II MEDI4736 PLUS OLAPARIB STUDY ELIGIBILITY CRITERIA - METASTATIC CASTRATE-RESISTANT
        PROSTATE CANCER

          -  Patients must have metastatic, progressive, castrate resistant prostate cancer
             (mCRPC).

          -  All patients must have at least one lesion deemed safe to biopsy and be willing to
             undergo a mandatory baseline biopsy.

          -  Patients must have received prior treatment with enzalutamide and/or abiraterone with
             the exception of patients who were treated with docetaxel and androgen deprivation
             therapy for metastatic castrate-sensitive prostate cancer and progressed on docetaxel
             treatment or who progress within one month of the last docetaxel dose.

          -  Patients must have undergone bilateral surgical castration or must agree to continue
             on GnRH agonists/antagonists for the duration of the study.

          -  Patients who have had progression of prostate cancer on prior docetaxel treatment for
             castrate sensitive disease are ineligible.

          -  Patients who have had prior treatment with PARPi are not eligible.

          -  Patients who have received radionuclide treatment within 6 weeks prior to the first
             dose of the study treatment are not eligible.

          -  Patients with any other concomitant or prior invasive malignancies are ineligible.